CBD Oil Was Safe and Well-Tolerated for Long COVID Symptoms in Small Trial

All 12 participants adhered to the treatment protocol for the full 21 weeks with no serious adverse events. Response rates for research assessments exceeded 90%. The study demonstrated feasibility of CBD treatment in long COVID, but the open-label design without a control group means efficacy conclusions cannot be drawn.

Single-arm open-label feasibility trial. 12 adults with diagnosed long COVID received up to 3 mL/day of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg THC/mL) for 21 weeks, followed by 3 weeks without treatment. Monthly patient-reported outcomes and daily symptom self-reports were collected via smartphone app. Wearable technology tracked heart rate, activity, sleep, and oxygen saturation.

Long COVID affects millions and has limited treatment options. This study establishes that CBD-dominant cannabis oil is feasible and safe to study in this population, paving the way for larger controlled trials. The high adherence rate is notable for a 21-week study.

CBD is being explored for multiple post-infectious syndromes due to its anti-inflammatory and immunomodulatory properties. Establishing safety and feasibility is the necessary first step before investing in larger efficacy trials.

Very small sample (n=12). No control group means no efficacy conclusions possible. Open-label design introduces placebo effects and expectancy bias. 11 of 12 participants were female, limiting generalizability. Recruitment challenges were noted.